1378 related articles for article (PubMed ID: 24120221)
1. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Prandoni P; Barbar S; Milan M; Vedovetto V; Pesavento R
Eur J Intern Med; 2014 Jan; 25(1):25-30. PubMed ID: 24120221
[TBL] [Abstract][Full Text] [Related]
2. The Optimal Duration of Anticoagulation in Patients with Unprovoked Venous Thromboembolism.
Prandoni P
Adv Exp Med Biol; 2017; 906():89-100. PubMed ID: 27620306
[TBL] [Abstract][Full Text] [Related]
3. Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
Prandoni P; Barbar S; Milan M; Campello E; Spiezia L; Piovella C; Pesavento R
Thromb Haemost; 2015 Jun; 113(6):1210-5. PubMed ID: 25119194
[TBL] [Abstract][Full Text] [Related]
4. Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis.
Prandoni P; Vedovetto V; Ciammaichella M; Bucherini E; Corradini S; Enea I; Cosmi B; Mumoli N; Visonà A; Barillari G; Bova C; Quintavalla R; Zanatta N; Pedrini S; Villalta S; Camporese G; Testa S; Parisi R; Becattini C; Cuppini S; Pengo V; Palareti G;
Thromb Res; 2017 Jun; 154():35-41. PubMed ID: 28407492
[TBL] [Abstract][Full Text] [Related]
5. [New evidence in the secondary prevention of thromboembolic disease].
Marchena Yglesias PJ
Med Clin (Barc); 2012 Oct; 139 Suppl 2():24-30. PubMed ID: 23498069
[TBL] [Abstract][Full Text] [Related]
6. The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
Akwaa F; Spyropoulos AC
Curr Med Res Opin; 2014 Nov; 30(11):2179-90. PubMed ID: 25105309
[TBL] [Abstract][Full Text] [Related]
7. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
Prandoni P; Noventa F; Ghirarduzzi A; Pengo V; Bernardi E; Pesavento R; Iotti M; Tormene D; Simioni P; Pagnan A
Haematologica; 2007 Feb; 92(2):199-205. PubMed ID: 17296569
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Loke YK; Kwok CS
J Clin Pharm Ther; 2011 Feb; 36(1):111-24. PubMed ID: 21198726
[TBL] [Abstract][Full Text] [Related]
9. Long-term benefits of preventing venous thromboembolic events.
Cohen AT
Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
[TBL] [Abstract][Full Text] [Related]
10. Optimal duration of anticoagulation in patients with unprovoked venous thromboembolism: the impact of novel anticoagulants.
Prandoni P; Milan M; Sarolo L; Zanon E; Bilora F
Int Angiol; 2017 Oct; 36(5):395-401. PubMed ID: 27982558
[TBL] [Abstract][Full Text] [Related]
11. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
12. [New treatments for venous thromboembolic disease].
Combe S; Büller HR
J Mal Vasc; 2011 Dec; 36 Suppl 1():S16-9. PubMed ID: 22177764
[TBL] [Abstract][Full Text] [Related]
13. Novel oral anticoagulants: a review of new agents.
Wanat MA
Postgrad Med; 2013 Jul; 125(4):103-14. PubMed ID: 23933899
[TBL] [Abstract][Full Text] [Related]
14. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
Marik PE; Cavallazzi R
PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
[TBL] [Abstract][Full Text] [Related]
15. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism.
Jiménez D; Díaz G; Marín E; Vidal R; Sueiro A; Yusen RD
Thromb Haemost; 2006 Mar; 95(3):562-6. PubMed ID: 16525588
[TBL] [Abstract][Full Text] [Related]
16. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.
Kyrle PA; Kammer M; Eischer L; Weltermann A; Minar E; Hirschl M; Heinze G; Eichinger S
J Thromb Haemost; 2016 Dec; 14(12):2402-2409. PubMed ID: 27696701
[TBL] [Abstract][Full Text] [Related]
17. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
18. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Quinlan DJ; Eriksson BI
Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
[TBL] [Abstract][Full Text] [Related]
19. Optimal duration of anticoagulation in patients with venous thromboembolism.
Prandoni P; Piovella C; Spiezia L; Dalla Valle F; Pesavento R
Indian J Med Res; 2011 Jul; 134(1):15-21. PubMed ID: 21808129
[TBL] [Abstract][Full Text] [Related]
20. Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism.
Kovacs MJ; Kahn SR; Wells PS; Anderson DA; Chagnon I; LE Gal G; Solymoss S; Crowther M; Perrier A; Ramsay T; Betancourt MT; White RH; Vickars L; Rodger MA
J Thromb Haemost; 2010 Sep; 8(9):1926-32. PubMed ID: 20561184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
